Arthritic PsoriasisPsA-RETINANCT07858591
Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study.
An observational study of Arthritic Psoriasis and Psoriasis (PsO), run by Bursa Yuksek Ihtisas Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye function, the dimensions of the foveal avascular zone (FAZ) supplied by this layer, and… Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Arthritic Psoriasis, Psoriasis (PsO), Retinal Vessels
- What is being tested?
- OCTA-SCP, OCTA-DCP and OCTA-RPC
- How many people
- 135 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2026to 31 Aug 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population consists of volunteers from among patients with psoriatic arthritis who are being followed at the study center's rheumatology clinic. The patient control group comprises volunteers diagnosed with psoriasis by a specialist dermatologist. Participants in the healthy control group are healthcare workers or patient companions matched for age and gender with the patient group and the patient control group.
Who may be able to join
- Volunteers diagnosed with psoriatic arthritis according to CASPAR criteria
- Volunteers diagnosed with psoriasis by a specialist dermatologist
- Hospital staff or patient companions with no chronic illnesses
Who cannot join
- Diabetes mellitus
- Cancer
- Pregnancy or lactation
- Chronic renal failure
- Glocome
- History of eye surgery
- History of eye trauma
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
Bursa, Yıldırım, 16130
Koray Ayar, 05325618450, ayarkoray@hotmail.com
Koray Ayar, Associated Proffessor (Dr.), +90 224-2955000 ext. 1648, ayarkoray@hotmail.com
About this study
Official title: Evaluation of Retinal Capillary Vascular Structures and the Foveal Avascular Zone in Patients With Psoriatic Arthritis.
In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Parameters such as the thickness of the choroid layer, which plays a crucial role in maintaining normal eye function, the dimensions of the foveal avascular zone (FAZ) supplied by this layer, and retinal vascular networks can be measured using non-invasive methods. OCTA (Optical Coherence Tomography Angiography) is an imaging tool that enables the non-invasive assessment of retinal microvascular densities and the measurement of the foveal avascular zone's dimensions. Studies conducted to date indicate that retinal capillary vessels and the dimensions of the foveal avascular zone are affected in rheumatological diseases, especially associated with systemic inflammation. This study aims to compare retinal capillary vessel density and foveal avascular zone dimensions in patients with psoriatic arthritis against those in a healthy population and in patients with psoriasis who do not have psoriatic arthritis, utilizing the non-invasive method of optical coherence tomography angiography.
Read the detailed description
In terms of blood flow per unit of tissue, the retina is one of the tissues with the highest blood flow in the body. Non-invasive methods allow for the measurement of-and the detection of changes in-the thickness of the choroid layer (which plays a crucial role in maintaining normal eye function), the foveal avascular zone (nourished by this layer), and the retinal vascular networks. OCTA (Optical Coherence Tomography Angiography) is an imaging tool capable of non-invasively assessing retinal microvascular densities and measuring the dimensions of the foveal avascular zone. Retinal microvascular structures can be affected by systemic pathologies, including various eye diseases. In recent years, there has been growing evidence indicating that retinal vessel densities-as detected by OCTA-are significantly altered and the dimensions of the foveal avascular zone differ in patients with connective tissue diseases, vasculitis, and spondylitis. Psoriatic arthritis is a common chronic inflammatory disease characterized by both spondyloarthropathy and peripheral arthritis involvement. There is currently no data in the literature regarding the status of the choroidal vasculature-a highly perfused tissue-in patients with psoriatic arthritis or its relationship with disease activity. In this study, we aimed to compare retinal capillary density and foveal avascular zone dimensions among patients with psoriatic arthritis, patients with psoriasis, and healthy individuals using OCTA. The study will also compare findings between subgroups of psoriatic patients with and without concomitant spondylitis.
- Conditions
- Arthritic Psoriasis, Psoriasis (PsO), Retinal Vessels
- Being tested
- OCTA-SCP, OCTA-DCP, OCTA-RPC, OCTA-FAZ
- Keywords
- Psoriatic arthritis
- Medical subject headings
- Arthritis, Psoriatic, Psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OCTA-SCPDiagnostic test
Vessel density of retinal superficial capillary plexus
OCTA-DCPDiagnostic test
Vessel density of retinal deep capillary plexus
OCTA-RPCDiagnostic test
Vessel density of retinal prepapillary capillaries
OCTA-FAZDiagnostic test
FAZ essessment parameters
| Study group | Role | What they receive |
|---|---|---|
| Psoriatic arthritis | Participants with psoriatic arthritis Receives: Diagnostic Test: OCTA-SCP; Diagnostic Test: OCTA-DCP; Diagnostic Test: OCTA-RPC; Diagnostic Test: OCTA-FAZ | |
| Psoriasis | Psoriasis participants with no other known systemic inflammatory disease Receives: Diagnostic Test: OCTA-SCP; Diagnostic Test: OCTA-DCP; Diagnostic Test: OCTA-RPC; Diagnostic Test: OCTA-FAZ | |
| Healthy controls | Patient companions or hospital staff with no known chronic illnesses Receives: Diagnostic Test: OCTA-SCP; Diagnostic Test: OCTA-DCP; Diagnostic Test: OCTA-RPC; Diagnostic Test: OCTA-FAZ |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retinal SCP, VD
Vessel density of retinal superficial capillary plexus
Measured: 1 day
Retinal DCP, VD
Vessel density of retinal deep capillary plexus
Measured: 1 day
Retinal RCP, VD
Vessel density of retinal prepapillary capillaries
Measured: 1 day
FAZ parameters
Foveal avasculary assessment parameters
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2026
- Study start1 Sep 2026
- Primary completion20 Aug 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arthritic PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 135 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Koray Ayar, Saglik Bilimleri Universitesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07858591
- Sponsor's protocol ID
- 2024-TBEK 2026/09-01
- Acronym
- PsA-RETINA
- Status last verified
- Sep 2026
- First submitted
- 29 Sep 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No